Differential survival benefit of curative versus non-curative intent treatment in a real-world cohort with early and intermediate-stage hepatocellular carcinoma
Our real-world data demonstrate that among patients with early-stage to intermediate-stage HCC, curative-intent treatment is associated with the best survival for patients with BCLC-0 and BCLC-A stage disease, while combination therapy yields the best outcomes in patients with BCLC-B stage disease.
Authors
- Sirisha Gaddipati
- Cindy Delgado (ORCID: https://orcid.org/0000-0002-7156-0107)
- Catherine Blandon (ORCID: https://orcid.org/0000-0001-6414-6787)
- Neelima Gaddipati
- David Goldberg
- David Kaplan
- Binu John
Institutions
- University of Miami (US)
- Jackson Memorial Hospital (US)
- Bruce W. Carter VA Medical Center (US)
- Philadelphia VA Medical Center (US)
- University of Pennsylvania (US)
- Florida Memorial University (US)
Publication Details
- Journal
- Hepatology Communications
- Published
- 2026-01-29
- DOI
- https://doi.org/10.1097/hc9.0000000000000891
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00